The pharmaceutical sector enters 2026 with confidence and ample capital to deploy following a strong second half of 2025 defined by precision-driven biopharma M&A. Acquirers are concentrating on distinctive science and partnerships that move promising assets faster through development while preserving options. Dealmakers are prioritizing disciplined deployment of capital and meticulous portfolio-shaping to secure high-quality innovation and scarce assets; these actions can offset looming market loss-of-exclusivity that will ramp up over the next four years and help sustain growth. The result is a market that will reward speed and judgment.
Read the full article: PwC US Deals 2026 Outlook: Pharmaceutical and Life Sciences //
Source: https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html